

**DISCLOSURE STATEMENT PURSUANT TO
THE PINK BASIC DISCLOSURE GUIDELINES**

QIAN YUAN BAIXING, INC.

A Nevada Corporation

601 Union Street Suite 4200

Seattle, WA 98101

(Company's Address)

(206) 923-9200

(Company's telephone number)

open

(Company's Website)

open

(Company's email)

7812 – Motion picture and video production

(Company's SIC Code)

QUARTERLY REPORT

For the Period Ending March 31, 2025

(the "Reporting Period")

Outstanding Shares

As of May 9, 2025, the number of shares outstanding of our Common Stock was:

91,641,747 shares

As of December 31, 2024, the Most Recent Fiscal Year End Reporting Period, the number of shares outstanding of our Common Stock was:

91,641,747 shares

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐

No: ☒

Indicate by check mark whether the company's shell company status has changed since the previous reporting period:

Yes: ☐

No: ☒

Change in Control

Indicate by check mark whether a Change in Control of the company has occurred over this reporting period:

Yes: ☐

No: ☒

Item 1. Name of the issuer and its predecessor (if any).

The name of the issuer is Qian Yuan Baixing, Inc. ("the Company"), formerly MDCorp., General Automotive Co., Utility Investment Recovery Inc., and Bridgefilms Inc. The Company was incorporated in the State of Nevada on October 7, 2005.

On September 16, 2013, a predecessor Company, General Automobile Company, was discharged under Chapter 7 bankruptcy by the State of Nevada.

On February 7, 2017, the Company filed a Form 15-12G, Certificate and Notice of Termination of Registration under Section 12(g) of the Securities Exchange of the 1934 Act.

The Company is currently in good standing in the State of Nevada.

Describe any trading suspension order issued by the SEC concerning the issuer or its predecessors:

NONE

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off or reorganization, either currently anticipated or that occurred within the past 12 months.

None

The address of the issuer's principal executive office:

601 Union Street Suite 4200.
Seattle, WA 98101

The address of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: ☒

Has the Company or any of its predecessors ever been in bankruptcy, receivership, or other similar proceeding in the past five years?

Yes: ☐

No: ☒

If Yes, provide additional details below:

Not applicable

Item 2. Security Information.

Transfer Agent:

Empire Stock Transfer Inc.
1859 Whitney Mesa Dr.
Henderson, NV 89014
Phone (702)818-5898
Email: info@empirestock.com

Publicly Quoted or Traded Securities:

Trading Symbol:	QYBX
Exact title and class of securities outstanding:	Common Stock
CUSIP:	74737T101
Par or Stated Value:	\$0.001 par value.
Total Shares Authorized:	100,000,000 as of May 9, 2025
Total Shares Outstanding:	91,641,747 as of May 9, 2025
Total number of shareholders of record:	108 as of May 9, 2025.

Other classes of authorized or outstanding equity securities:

Trading Symbol:	None
Exact title and class of securities outstanding:	Preferred Stock
CUSIP:	None
Par or Stated Value:	\$0.001 par value.
Total Shares Authorized:	10,000,000 as of May 9, 2025
Total Shares Outstanding:	-0- shares as of May 9, 2025
Total number of shareholders of record:	-0- as of May 9, 2025.

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

Our common stock is entitled to one vote per share on all matters submitted to a vote of the stockholders, including the election of directors.

Subject to any preferential rights of any outstanding series of preferred stock created by our board of directors, the holders of shares of our common stock will be entitled to such cash dividends as may be declared from time to time by our board of directors from funds available, therefore. No dividend has been declared.

Holders of our common stock have no pre-emptive rights, no conversion rights and there are no redemption provisions applicable to our common stock.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

The board of directors has the authority to provide by resolution for the issuance of shares of Preferred Stock in one or more series not exceeding the aggregate number of shares of Preferred Stock authorized by these Articles, and to prescribe with respect to each such series the voting powers, if any, designations, preferences, and relative, participating, optional, or other special rights, and the qualifications, limitations, or restrictions relating thereto, including, without limiting the generality of the foregoing: the voting rights relating to the shares of Preferred Stock of any series (which voting rights, if any, may be full or limited, may vary over time, and may be applicable generally or only upon any stated fact or event); the rate of dividends (which may be cumulative or non-cumulative), the condition or time for payment of dividends and the preference or relation of such dividends to dividends payable on any other class or series of capital stock; the rights of holders of Preferred Stock of any series in the event of liquidation, dissolution, or winding up of the affairs of the Corporation; the rights, if any, of holders of Preferred Stock of any series to convert or exchange such shares of Preferred Stock of such series for shares of any other class or series of capital stock or for any other securities, property, or assets of the Corporation or any subsidiary (including the determination of the price or prices or the rate or rates applicable to such rights to convert or exchange and the adjustment thereof, the time or times during which the right to convert or exchange shall be applicable, and the time or times during which a particular price or rate shall be applicable); whether the shares of any series of Preferred Stock shall be subject to redemption by the Corporation and if subject to redemption, the times, prices, rates, adjustments and other terms and conditions of such redemption. The powers, designations, preferences, limitations, restrictions and relative rights may be made. The Company has no preferred shares outstanding.

3. Describe any other material rights of common or preferred stockholders.

None

4. Describe any material modifications to the rights of the holders of the company's securities that have occurred over the reporting period covered by this report.

None

Item 3. Issuance History.

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes in the Number of Outstanding Shares.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: ☒ Yes: ☐ (If yes, you must complete the table below)

As of March 31, 2025, the following shares were not issued:

On March 3, 2023, the Company acquired all the outstanding shares of Hangzhou Mai Jin Li Biotechnology Co., Ltd (“Mai Jin Li”), for 3,000,000 unregistered shares of the Company’s common stock. The Company’s common stock was valued at \$9,600 or \$0.0032 per share. As of May 9, 2025 the shares have not been issued.

B. Debt Securities, including Promissory and Convertible Notes.

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer’s equity securities:

No: ☐ Yes: ☒ (If yes, you must complete the table below)

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion	Name of Noteholder (entities must disclose individual with voting / investment control person(s) for any entities listed.)	Reason for Issuance (e.g., Loan, Services, etc.)
June 29, 2017	100,000	138,795	June 22, 2022	Indebtedness convertible at an exercise price of the 10-day VWAP of Company common stock prior to the date of conversion	-	13,219,000	PMT Advisory Ltd. HK (1)	Loan
	Total Outstanding Balance:	138,795		Total shares	-	13,219,000		

The below space provides any additional details, including footnotes to the table above:

(1) A corporation controlled by Shawn Mesaros, the Company’s former CEO.

Item 4. Issuer’s Business, Products and Services.

A. Summary of the Issuer’s Business Operations.

Current Operations

Qian Yuan Baixing, Inc. ("The Company") is a Nevada C Corporation that was originally formed as Bridgefilms Inc. on October 7, 2005.

On January 25, 2018, the following individuals were appointed to the Company. Zhi Cao was appointed Chief Executive Officer, President and a Director. Zhujun Cao was appointed Chief Financial Officer and Treasurer. Jianhao Li was appointed Secretary. In addition, Shawn Mesaros resigned as the Company’s CEO, COO, President, Treasurer, Secretary and Director and became an advisor to the Company.

On April 12, 2018, the Company filed with the Secretary of State of the State of Nevada a Certificate of Amendment, to change the name of the Company to “Qian Yuan Baixing, Inc.”

On July 13, 2021, the Company acquired 100% of the assets of Panjin Chunqiu Century Industrial Co., Ltd., (“Chunqiu”) a subsidiary of Qianyuan International Group, located in Kowloon, Hong Kong. The Company granted 2,000,000 restricted shares of the Company’s common stock in exchange for the assets of Chunqiu. The shares were valued at \$98,000 or \$0.049 per share. Chunqiu focuses on selling goods and services on the internet.

Chunqiu, was founded in May 2017, located in China's Liaoning Internet building, focusing on social networking, an internet shopping mall and health care services. In 2019, the company began to pay more attention to social networking, e-commerce and an internet shopping mall. With the concept of "high quality products and quality service" as the operation concept, Chunqiu should speed up the convenience, specialization and digitalization of small shops, upgrade the gathering areas, innovative services and business environment as the main direction to stabilize employment, expand domestic demand and promote consumption. With the goal of enhancing economic vitality, Chunqiu will promote the formation of a multi-level and multi-category small store economic development system to meet the people's growing needs for a better life. The platform of Chunqiu will lead to a larger online presence and strive to reach 10 million people in 100 cities and 1000 districts within five years.

On March 3, 2023, the Company acquired all the outstanding shares of Hangzhou Mai Jin Li Biotechnology Co., Ltd (“Mai Jin Li”), a privately held limited liability company organized under the laws of the People’s Republic of China. Fifty percent of Mai Jin Li’s outstanding shares were owned by the Company’s CEO and the remaining shares by an unrelated individual. The Company issued 3,000,000 unregistered shares of the Company’s common stock for 100% of the outstanding shares of Mai Jin Li. The Company’s common stock was valued at \$9,600 or \$0.0032 per share. Mai Jin Li is an enterprise specializing in the production, processing, distribution and professional technical consulting services of soft capsules for supplements.

Mai Jin Li It is positioned to provide high-quality health foods for the national market and build China's high-end high-quality health food brand. Mai Jin Li will utilize the upstream industrial chain of high-end high-quality health food industry. It will use capital to restructure high-end high-quality health food enterprises.

The Company plans to implement the following initiative for Mai Jin Li:

1. Improve product quality:

We will improve product appearance and internal quality. We will Increase the scientific and technological content of products and gradually transition to the development of varieties with independent intellectual property rights.

2. Strengthen scientific and technological cooperation:

We will form alliances in China and with pharmaceutical factories in developed countries; strengthen horizontal links, focus on new product development, adjust product structure, and gradually integrate into the international market. With the goal of positioning our Company with international alliances to promote exports and scientific research.

3. Vigorously develop varieties of traditional Chinese medicine:

Among the traditional Chinese medicine prescriptions, there are many ancient, proven and beneficial prescriptions, which can supplement without dryness, absorb well and have little side effects. We will carry forward the advantages of traditional Chinese medicine with unique effects on rehabilitation and health care, create traditional medicine, folk medicine and health care medicine with Chinese characteristics, strive to play the advantages of traditional Chinese medicine, and actively explore the international market.

4. Integrated production and marketing:

Panjin Chunqiu Century Industrial Co., Ltd. controls the online and offline sales, Mai Jin Li focuses on the production of high-quality, high-efficiency and high-tech products to form a smooth production and marketing chain with complementary industries.

With the acquisition of Hangzhou Mai Jin Li Biotechnology Co., Ltd on March 3, 2023, the Company has reported four consecutive quarters of operating profits and positive cash flows from operations. As of June 30, 2024, the Company is no longer considered to have a going concern.

B. Describe any subsidiaries, parents or affiliated companies, if applicable, and a description of their contact information for the business, officers, directors, managers or control persons.

On July 13, 2021, the Company acquired 100% of the assets of Panjin Chunqiu Century Industrial Co., Ltd., (“Chunqiu”) a subsidiary of Qian Yuan International Group, located in Kowloon, Hong Kong.

On March 3, 2023, the Company acquired all the outstanding shares of Hangzhou Mai Jin Li Biotechnology Co., Ltd (“Mai Jin Li”). Mai Jin Li is an enterprise specializing in the production, processing, distribution and professional technical consulting services of soft capsules for supplements.

C. Principal Products or Services, and Their Markets.

Panjin Chunqiu Century Industrial Co., Ltd., (“Chunqiu”) focuses on selling goods and services on the internet. Qian Yuan Baixing, Inc. will directly or indirectly capitalize its subsidiaries in order to drive the best economics we feel are available for each technology or solution, allowing our subsidiary managers to directly fund themselves or where appropriate or where it creates more value, and use equity in the Company to drive investment from our corporate entity. Qian Yuan Baixing, Inc. has long recognized that Asia is the home for more than 50% of the world's population, yet healthcare spending per-capita remains some 75% below developed country averages. Qian Yuan Baixing, Inc. seeks to utilize technology, distribution and brand equity to develop MedTech more rapidly and biotechnology solutions in the local market. We feel this makes Qian Yuan Baixing, Inc. one of the most unique platforms through which we can accelerate local market product development and distribution.

Hangzhou Mai Jin Li Biotechnology Co., Ltd (“Mai Jin Li”). is an enterprise specializing in the production, processing, distribution and professional technical consulting services of soft capsules for supplements.

Item 5. Issuer's Facilities.

Description of Corporate Offices

Since approximately March 2017, the Company's corporate offices have been located at 601 Union Street Suite 4200, Seattle, WA 98101, which is property controlled by our former CEO. This office space is provided, on a month-to-month basis, by our former CEO at no charge.

We believe that our current facilities are adequate for our operations as currently conducted and if additional facilities are required, that we can obtain them at commercially reasonable prices.

The Company does not lease any assets, properties or facilities.

Item 6. Officers, Directors and Control Persons.

The table below provides information, as of May 9, 2025, regarding any officers, or directors of the company, individuals or entities controlling more than 5% of any class of the issuer's securities, or any person that performs a similar function, regardless of the number of shares they own. If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.

Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, 5% Control person)	Residential Address (City /and State Only) (Include Country if outside U.S.)	Number of shares owned (List common, preferred, warrants and options separately)	Share Type/Class of Shares Owned	Ownership Percentage of Class Outstanding Shares Owned (undiluted) (1)
Zhi Cao	CEO, President, Director	Qinhuangdao City, Peoples Republic of China	None	None	None
Zhujun Cao	CFO and Treasurer	Qinhuangdao City, Peoples Republic of China	None	None	None
Jianhao Li	Secretary	Qinhuangdao City, Peoples Republic of China	None	None	None
Qinhuangdao Baixing Communication & Tech LTD. (2)	Related Company	Qinhuangdao City, Peoples Republic of China	70,000,000	Common	76.4%

The below space provides any additional details, including footnotes to the table above:

- (1) As of May 9, 2025, there were 91,641,747 shares of common stock and -0- shares of preferred stock shares issued and outstanding.
- (2) Zhi Coa, the Company's CEO, has voting and investment control and resides in Qinhuangdao City, Peoples Republic of China.

Item 7. Legal/Disciplinary History

A. Identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. An indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial or investment related, insurance or banking activities;

None

3. A finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

None

5. An order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

6. A U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incident to the business, to which the issuer or any of its subsidiaries is a party or which any of their property is subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceeding known to be contemplated by governmental authorities.

None

Item 8. Third Party Providers

Securities Counsel (Counsel preparing Attorney Letters):

Thomas E, Puzzo
Law Offices of Thomas E, Puzzo, PLLC
8823 44th Ave. NE
Seattle, Washington 98105
Phone no.: (206) 522-2256

Accountant or Auditor:

Rick Basse, CPA
Rick Basse Consulting, PLLC
244 Majestic Oak Drive
New Braunfels, Texas 78132
Phone no.: (210) 347-0374
Email: rick.basse@gmail.com

Investor Relations:

Shawn Mesaros
CTM Advisory, LTD
Two Union Square 601 Union Street
Suite # 4200
Seattle, WA 98101

All other means of Investor Communication:

Twitter: None
Discord: None
LinkedIn: None
Facebook: None
[Other] None

Other Service Providers:

The name(s) of other service provider(s), including counsel, advisor(s) or consultant(s) that assisted, advised, prepared or provided information with respect to this disclosure statement, or provided assistance or services to the Company during the Reporting Period are as follows:

Name: None

Firm:

Nature of Services: Address:

Phone: Email:

Item 9. Financial Statements.

A. This Disclosure Statement was prepared by (name of individual):

Name: Rick Basse, CPA

Title: Owner of Rick Basse Consulting, PLLC

Relationship to Issuer: Accountant engaged by Company.

B. The following financial statements were prepared in accordance with:



U.S. GAAP



IFRS

C. The financial statements for this reporting period were prepared by (name of individual):

Name: Rick Basse, CPA

Title: Owner of Rick Basse Consulting, PLLC

Relationship to Issuer: Accountant engaged by Company.

The qualifications of the person who prepared the financial statements: The accountant is a CPA as recognized by the Texas State Board of Public Accountancy.

The following financial statements described below are provided and incorporated by this reference for the most recent fiscal year or quarter:

- Consolidated Balance Sheets;
- Consolidated Statements of Operations;
- Statement of Changes in Shareholders' Equity
- Statement of Cash Flows;
- Financial Notes

Attached as Exhibit A to this Quarterly Report are our financial statements and notes to financial statements for the three months ended March 31, 2025.

Management's Discussion and Analysis or Plan of Operation.

A. Plan of Operations

With our July 13, 2021 acquisition of Panjin Chunqiu Century Industrial Co., Ltd., ("Chunqiu"), and our March 3, 2023 acquisition of Hangzhou Mai Jin Li Biotechnology Co., Ltd ("Mai Jin Li"), we will be focusing on executing the business plan for our new acquisitions, selling goods and services on the internet and the production, processing, distribution and professional technical consulting services of soft capsules. For the three months ending March 31, 2025 and 2024, we had revenues of \$860,200 and \$1,057,158, respectively, and incurred net income of \$31,335 and \$80,505 for the three months ended March 31, 2025 and 2024, respectively. At March 31, 2025, we had an accumulated deficit since inception of \$9,090,315.

With the acquisition of Hangzhou Mai Jin Li Biotechnology Co., Ltd on March 3, 2023, the Company has reported five consecutive quarters of operating profits and positive cash flows from operations as of June 30, 2024, thus, the Company is no longer considered having a going concern. The Company will continue to monitor its operations to ensure there is no going concern considerations.

Liquidity and Capital Resources

As of March 31, 2025, we had cash of \$1,164,865 and working capital of \$1,018,399. This compares to cash of \$1,159,715 and working capital of \$929,542 at December 31, 2024.

B. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Results of Operations for the three months ended March 31, 2025 compared to the three months ended March 31, 2024:

Overview. Qian Yuan Baixing, Inc. is a Nevada corporation, originally formed on October 7, 2005. Qian Yuan Baixing, Inc. is attempting to grow by selling consumer goods and services on the internet. The Company has generated sales of \$860,200 and \$1,057,158 for the three months ending March 31, 2025 and 2024, respectively. The Company generated net income of \$31,335 and \$80,505 for the three months ending March 31, 2025 and 2024, respectively. The net income decrease of \$49,170 is attributable to the factors discussed below.

Revenues. We had revenues of \$860,200 and \$1,057,158 for the three months ending March 31, 2025 and 2024, respectively, the decrease of \$196,958 is attributable to a slowing economy during the three months ending March 31, 2025.

Gross Margin. Once the cost of revenue and other expenses to generate revenue are considered, we had gross margins of \$180,596 and 21% of revenue and \$330,340 and 30% of revenues from our operations for the three months ended March 31, 2025 and 2024, respectively. The \$139,744 decrease in gross margin is attributable to a slowing economy.

Operating Expenses. Our operating expenses were \$150,513 and \$246,378 for the three months ending March 31, 2025 and 2024, respectively. The decrease of \$95,865 was primarily attributable to an approximate \$62,000 decrease in other general and administrative expenses, an approximate \$20,000 decrease in salaries from the combined efficiency of our two subsidiaries and an approximate \$12,000 decrease in amortization and depreciation expense and an approximate \$2,000 decrease in professional fees.

Other Income (Expense). Our other income (expense) was \$4,629 and \$6,543 for the three months ending March 31, 2025 and 2024, respectively. The \$1,914 decrease in other income was from a decrease in other expense of \$387 and a \$1,527 decrease in interest income.

Capital Structure and Resources

As of March 31, 2025, we had assets of \$2,681,921 consisting of cash of \$1,164,865, accounts receivable of \$1,059,039, inventory of \$194,274, prepaid expenses of \$6,087, cash advances to suppliers of \$18,769, other current assets of \$9,473, property and equipment of \$130,225 (net of accumulated depreciation), patents of \$806 (net of accumulated amortization), goodwill of 78,911 and other assets of \$19,462.

We had total liabilities of \$1,434,128 as of March 31, 2025 consisting of accounts payable for \$1,018,602, accrued expenses of \$140,197, shareholder advances of \$175,239 and a \$100,000 related party convertible promissory note payable.

At March 31, 2025, we had total stockholders' equity of \$1,247,793. We have an accumulated deficit of \$9,090,315 at March 31, 2025.

Cash of (\$306,524) and \$304,596 was provided (used) by operating activities for the three months ending March 31, 2025 and 2024, respectively.

Cash of \$25,136 was used in investing activities for the three months ended March 31, 2024 from the acquisition of equipment.

Cash of \$303,210 was provided by financing activities for the three months ended March 31, 2025 from advances from suppliers of \$302,330 and shareholder advances of \$880. Cash of \$417,106 was provided by financing activities for the three months ended March 31, 2024 from customer advances of \$607,950 and \$989 of shareholder advances offset by repayments to suppliers of \$191,833.

Item 10. Issuer's Certifications.

Principal Executive Officer:

I, Zhi Cao, as CEO, President, and Director, certify that:

1. I have reviewed this Quarterly Report of Qian Yuan Baixing, Inc.

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the restated financial statement, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Dated: May 9, 2025

Qian Yuan Baixing, Inc.

By /s/ Zhi Cao
Zhi Cao, CEO, President, Director

Principal Financial Officer:

I, Zhujun Cao as CFO and Treasurer, certify that:

1. I have reviewed this Quarterly Report of Qian Yuan Baixing, Inc.

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the restated financial statement, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Dated: May 9, 2025

Qian Yuan Baixing, Inc.

By /s/ Zhujun Cao
Zhujun Cao, CFO, Treasurer

Exhibit A

QIAN YUAN BAIXING, INC.

601 Union Street Suite 4200

Seattle, WA 98101

Financial Statements and Notes

For the Three months ended March 31, 2025 and 2024

Qian Yuan Baixing, Inc.
Consolidated Balance Sheets (Unaudited)

	March 31, 2025	December 31, 2024
Assets		
Current assets:		
Cash	\$ 1,164,865	\$ 1,159,715
Accounts receivable	1,059,039	533,311
Inventory	194,274	278,450
Prepaid expenses	6,087	4,561
Cash advances to suppliers	18,789	321,119
Other current assets	9,473	9,418
Total current assets	<u>2,452,527</u>	<u>2,306,574</u>
Other assets		
Property and equipment, net of accumulated depreciation of \$254,130 and \$216,926 at March 31, 2025 and December 31, 2024, respectively	130,225	165,198
Patents, net of accumulative amortization of \$1,674 and \$1480 at March 31, 2025 and December 31, 2024, respectively	806	986
Goodwill	78,911	78,911
Other assets	19,452	33,357
Total other assets	<u>229,394</u>	<u>278,452</u>
Total Assets	<u>\$ 2,681,921</u>	<u>\$ 2,585,026</u>
Liabilities and Stockholders' Equity (Deficiency)		
Current liabilities:		
Accounts payable	\$ 1,018,602	\$ 952,676
Accrued expenses	140,197	149,907
Stockholders advances	175,329	174,449
Related party convertible promissory note payable	100,000	100,000
Total current liabilities	<u>1,434,128</u>	<u>1,377,032</u>
Commitments and contingencies	-	-
Stockholders' Equity (Deficiency):		
Preferred stock, \$0.001 par value; 10,000,000 shares authorized, -0- shares issued and outstanding as of March 31, 2025 and December 31, 2024	-	-
Common stock, \$0.001 par value, 100,000,000 shares authorized 91,641,747 issued and outstanding as of March 31, 2025 and December 31, 2024	91,642	91,642
Additional paid-in capital	10,292,030	10,292,030
Common stock to be issued	9,600	9,600
Accumulated other comprehensive income (loss)	(55,164)	(63,628)
Accumulated deficit	(9,090,315)	(9,121,650)
Total stockholders' equity (deficiency)	<u>1,247,793</u>	<u>1,207,994</u>
Total Liabilities and Stockholders' Equity (Deficiency)	<u>\$ 2,681,921</u>	<u>\$ 2,585,026</u>

The accompanying notes are an integral part of these consolidated financial statements.

Qian Yuan Baixing, Inc.
Consolidated Statements of Operations (unaudited)

	For the Three Months Ended	
	March 31, 2025	March 31, 2024
Revenue	\$ 860,200	\$ 1,057,158
Cost of Revenue	<u>679,604</u>	<u>736,818</u>
Gross margin	180,596	320,340
Operating expenses:		
Salaries	\$ 106,997	\$ 127,218
Professional fees	880	2,990
Amortization and depreciation expense	37,399	49,245
General and administrative expenses	5,237	66,925
Total operating expenses	<u>150,513</u>	<u>246,378</u>
Net operating income (loss)	30,083	73,962
Other income (expense):		
Other income (expense)	(9)	378
Interest income (expense)	<u>4,638</u>	<u>6,165</u>
Total other income (expense)	<u>4,629</u>	<u>6,543</u>
Income before provision for taxes	34,712	80,505
Provision for income taxes	<u>3,377</u>	<u>-</u>
Net income (loss)	<u>\$ 31,335</u>	<u>\$ 80,505</u>
Basic income (loss) per share	<u>\$ 0.00</u>	<u>\$ 0.00</u>
Diluted income per share	<u>\$ 0.00</u>	<u>\$ 0.00</u>
Weighted average number of common shares outstanding - basic	91,641,747	91,641,747
Weighted average number of common shares outstanding - diluted	104,766,400	156,684,439

The accompanying notes are an integral part of these consolidated financial statements.

Qian Yuan Baixing, Inc.
Statement of Changes in Stockholders' Deficiency (Unaudited)

	Common Stock		Preferred Stock		Additional Paid-In Capital	Common Stock to be Issued	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Total Stockholders' Equity (Deficiency)
	Shares	Amount	Shares	Amount					
For the Three Months Ended March 31, 2024									
Balance at December 31, 2023	91,641,747	\$ 91,642	-	\$ -	\$ 10,292,030	\$ 9,600	\$ (29,422)	\$ (9,421,975)	\$ 941,875
Other comprehensive income (loss)	-	-	-	-	-	-	(17,754)	-	(17,754)
Net income (loss)	-	-	-	-	-	-	-	80,505	80,505
Balance at March 31, 2024	91,641,747	\$ 91,642	-	\$ -	\$ 10,292,030	\$ 9,600	\$ (47,176)	\$ (9,341,470)	\$ 1,004,626
For the Three Months Ended March 31, 2025									
Balance at December 31, 2024	91,641,747	\$ 91,642	-	\$ -	\$ 10,292,030	\$ 9,600	\$ (63,628)	\$ (9,121,650)	\$ 1,207,994
Other comprehensive income (loss)	-	-	-	-	-	-	8,464	-	8,464
Net income (loss)	-	-	-	-	-	-	-	31,336	31,336
Balance at March 31, 2025	91,641,747	\$ 91,642	-	\$ -	\$ 10,292,030	\$ 9,600	\$ (55,164)	\$ (9,090,314)	\$ 1,247,794

The accompanying notes are an integral part of these consolidated financial statements.

Qian Yuan Baixing, Inc.
Statements of Cash Flows (Unaudited)

	For the Three Months Ended	
	March 31, 2025	March 31, 2024
Cash flows from operating activities:		
Net loss	\$ 31,335	\$ 80,505
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation expense	34,973	49,552
Amortization of Intangibles	180	214
Gain on acquisition	-	-
Changes in operating assets and liabilities:		
Accounts receivable	(525,728)	(60,908)
Inventory	84,176	12,148
Prepaid expenses	(1,526)	(4,669)
Other current assets	-	144
Other assets	13,905	18,898
Accounts payable	65,871	272,103
Accrued expenses	(9,710)	(63,391)
Net cash provided (used) by operating activities	<u>(306,524)</u>	<u>304,596</u>
Cash flows from investing activities:		
Acquisition of equipment	-	(25,136)
Net cash used in investing activities	<u>-</u>	<u>(25,136)</u>
Cash flows from financing activities		
Shareholder advances	880	989
Advances (repayments) from/to suppliers	302,330	(191,833)
Customer advances	-	607,950
Net cash provided by financing activities	<u>303,210</u>	<u>417,106</u>
Net increase (decrease) in cash	(3,314)	696,566
Effect of foreign exchange adjustment	8,464	(17,754)
Cash - beginning of the year	1,159,715	328,681
Cash - end of the quarter	<u>\$ 1,164,865</u>	<u>\$ 1,007,493</u>
Supplemental disclosures:		
Interest paid	<u>\$ -</u>	<u>\$ -</u>
Taxes Paid	<u>\$ 3,377</u>	<u>\$ -</u>

The accompanying notes are an integral part of these consolidated financial statements.

QIAN YUAN BAIXING, INC.
Notes to Financial Statements (Unaudited)
As of March 31, 2025

NOTE 1 – ORGANIZATION

Description of Business

Qian Yuan Baixing, Inc. ("The Company") is a Nevada C Corporation that was originally formed as Bridgefilms Inc. on October 7, 2005.

On January 25, 2018, the following individuals were appointed to the Company. Zhi Cao was appointed Chief Executive Officer, President and a Director. Zhujun Cao was appointed Chief Financial Officer and Treasurer. Jianhao Li was appointed Secretary. In addition, Shawn Mesaros resigned as the Company's CEO, COO, President, Treasurer, Secretary and Director and became an advisor to the Company.

On April 12, 2018, the Company filed with the Secretary of State of the State of Nevada a Certificate of Amendment, to change the name of the Company to "Qian Yuan Baixing, Inc."

On July 12, 2018, the Company filed with the Secretary of State of the State of Nevada to increase the authorized shares from 90,000,000 to 100,000,000.

On July 13, 2021, the Company acquired 100% of the assets of Panjin Chunqiu Century Industrial Co., Ltd., ("Chunqiu") a subsidiary of Qianyuan International Group, located in Kowloon, Hong Kong. The Company granted 2,000,000 restricted shares of the Company's common stock in exchange for the assets of Chunqiu. The shares were valued at \$98,000 or \$0.049 per share. Chunqiu focuses on selling goods and services on the internet.

On March 3, 2023, the Company acquired all the outstanding shares of Hangzhou Mai Jin Li Biotechnology Co., Ltd ("Mai Jin Li"), a privately held limited liability company organized under the laws of the People's Republic of China. Fifty percent of Mai Jin Li's outstanding shares were owned by the Company's CEO and the remaining shares by an unrelated individual. The Company issued 3,000,000 unregistered shares of the Company's common stock for 100% of the outstanding shares of Mai Jin Li. The Company's common stock was valued at \$9,600 or \$0.0032 per share. Mai Jin Li is an enterprise specializing in the production, processing, distribution and professional technical consulting services of soft capsules for supplements.

With the acquisition of Hangzhou Mai Jin Li Biotechnology Co., Ltd on March 3, 2023, the Company has reported five consecutive quarters of operating profits and positive cash flows from operations as of June 30, 2024. As of June 30, 2024, the Company is no longer considered a going concern.

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America.

Use of Estimates

In preparing financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheet and revenue and expenses in the statement of expenses. Actual results could differ from those estimates.

Segment Reporting

The Company operates within two reportable operating segments, being selling goods and services on the internet and the production, processing, distribution and professional technical consulting services of soft capsules for supplements. The Company has identified its chief executive officer as its chief operating decision maker ("CODM"), who regularly reviews the Company's performance and allocates resources based on information reported at the consolidated entity level.

Reclassifications

Certain prior year amounts have been reclassified for comparative purposes to conform to the current year's financial statement presentation. These reclassifications had no effect on previously reported results of operations.

Cash and Cash Equivalents

For the purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

Accounts Receivable

Accounts receivables are recorded at the invoiced amount and are stated net of an allowance for doubtful accounts. The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the existing accounts receivable. The allowance is based on historical collection data and current franchisee information. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. At March 31, 2025, no allowance for doubtful accounts was deemed necessary. The accounts receivable balance was \$1,059,039 and \$533,311 at March 31, 2025 and December 31, 2024, respectively.

Inventory

Inventories are valued at the lower of cost (determined on a weighted average basis) or market. Management compares the cost of inventories with the market value and allowance is made to write down inventories to market value, if lower. The Company's inventory consists of products available for sale. The Company evaluated the inventory at March 31, 2025 and determined no inventory reserve was necessary.

A summary of the Company's inventory as of March 31, 2025 and December 31, 2024 is as follows:

Type	March 31, 2025	December 31, 2024
Mai Jin Li:		
Raw Materials	\$ 144,409	\$ 218,860
Supplements held for sale	3,842	4,523
Subtotal	148,251	223,383
Chunqiu:		
Personal hygiene items for sale on the internet	46,023	55,067
Total Inventory	\$ 194,274	\$ 278,450

Prepaid Expenses

The Company considers all items incurred for future services to be prepaid expenses. The prepaid expenses were \$6,087 and \$4,561 at March 31, 2025 and December 31, 2024, respectively, consisting of the OTC Markets semi-annual fee and various other items.

Related Parties

The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions.

Pursuant to Section 850-10-20 the Related parties include a) affiliates of the Company; b) Entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825-10-15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) Other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

Cash Advances to Supplier

The Company will advance funds to supplier on a short-term basis. The advances are non-interest bearing and are due on demand. The supplier advances were \$18,789 and \$321,119 at March 31, 2025 and December 31, 2024, respectively.

Property and Equipment

Property and equipment is recorded at cost and depreciated on the straight-line method over the estimated useful lives. Expenditures for normal repairs and maintenance are charged to expense as incurred. The cost and related accumulated depreciation of assets sold or otherwise disposed of are removed from the accounts, and any gain or loss is included in operations.

The Company recorded depreciation expenses of \$37,304 and \$49,069 for the three months ended March 31, 2025 and 2024, respectively.

Patents

The Company records the cost to acquire a patent as the initial asset cost. When the Company files for a patent application, this cost will include the filing and registration, documentation, and other legal fees associated with filing the application and legal costs to get the patent to be granted. Once the patents are approved and in use, and assuming no litigations expenses, the Company amortizes the patent cost over the useful life using the straight-line method. The amortization period will not exceed the lifespan of the protection afforded by the patent. If the expected useful life of the patent is even shorter, the Company will use the useful life for amortization purposes. Thus, the shorter length of a patent's useful life and its legal life will be used for the amortization period.

Goodwill

The Company test goodwill for impairment on an annual basis, or more frequently if circumstances, such as material deterioration in performance, indicate reporting unit carrying values may exceed their fair values. When evaluating goodwill for impairment, we may first perform a qualitative assessment to determine if the fair value of the reporting unit is more likely than not greater than its carrying amount. If we do not perform a qualitative assessment or if the fair value of the reporting unit is not more likely than not greater than its carrying amount, we calculate the implied estimated fair value of the reporting unit. If the carrying amount of goodwill exceeds the implied estimated fair value, an impairment charge to current operations is recorded to reduce the carrying value to the implied estimated fair value. As of December 31, 2024, no impairment of goodwill was deemed necessary.

Commitments and Contingencies

The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time, that these matters will have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company's business, financial position, and results of operations or cash flows.

Revenue Recognition

Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company's performance obligations are transferred to customers at a point in time, typically upon delivery.

Concentrations of Risk

Cash and cash equivalents deposited with financial institutions are insured by the Federal Deposit Insurance Corporation ("FDIC"). The Company did not hold cash in excess of FDIC insurance coverage at a financial institution as of March 31, 2025.

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based derivative financial instruments, The Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

Fair Value Measurements

In September 2006, the FASB issued ASC 820 which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The provisions of ASC 820 were effective January 1, 2008.

As defined in ASC 820, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observations of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).

The three levels of the fair value hierarchy defined by ASC 820 are as follows:

Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities.

Level 2 – Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.

Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value.

The Company did not identify any assets or liabilities that are required to be adjusted on the balance sheet at fair value in accordance with ASC 825-10 as of March 31, 2025 and December 31, 2024.

Income Tax Provisions

The Company’s policy is to provide for deferred income taxes based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates that will be in effect when the differences are expected to reverse. On January 1, 2023, the U.S. federal corporate income tax rate was 21%. We did not provide any current or deferred U.S. federal income tax provision or benefit for any of the periods presented because we have experienced operating losses since inception. When it is more likely than not that a tax asset cannot be realized through future income the Company must allow for this future tax benefit. We provided a full valuation allowance on the net deferred tax asset, consisting of net operating loss carryforwards, because management has determined that it is more likely than not that we will not earn sufficient income to realize the deferred tax assets during the carryforward period.

The Company is not aware of any uncertain tax position that, if challenged, would have a material effect on the financial statements for the three months ended March 31, 2025 or during the prior three years applicable under FASB ASC 740. We did not recognize any adjustment to the liability for uncertain tax position and therefore did not record any adjustment to the beginning balance of accumulated deficit on the consolidated balance sheet. All tax returns for the Company remain open for examination.

Net Income (Loss) Per Common Share

Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period. The weighted average number of common shares outstanding and potentially outstanding common shares assumes that the Company incorporated as of the beginning of the first period presented.

There were approximately 16,219,000 potentially dilutive shares outstanding as of March 31, 2025 from the Company’s related party convertible promissory note and common stock to be issued for the acquisition of Mai Jin Li on March 3, 2023 .

Cash Flows Reporting

The Company adopted paragraph 230-10-45-24 of the FASB Accounting Standards Codification for cash flows reporting, classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“Indirect method”) as defined by paragraph 230-10-45-25 of the FASB Accounting Standards Codification to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments. The Company reports the reporting currency equivalent of foreign currency cash flows, using the current exchange rate at the time of the cash flows and the effect of exchange rate changes on cash held in foreign currencies is reported as a separate item in the reconciliation of beginning and ending balances of cash and cash equivalents and separately provides information about investing and financing activities not resulting in cash receipts or payments in the period pursuant to paragraph 830-230-45-1 of the FASB Accounting Standards Codification.

Recently Issued Accounting Standards

During the three months ended March 31, 2025, there were several new accounting pronouncements issued by the FASB. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s financial statements.

In November 2023, the FASB issued ASU 2023 - 07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures” (“ASU 2023 - 07”). The amendments in ASU 2023 - 07 require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating officer decision maker (“CODM”), as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. ASU 2023 - 07 requires that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure (s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. Public entities will be required to provide all annual disclosures currently required by FASB ASC Topic 280, “Segment Reporting,” (“ASC 280”) in interim periods, and entities with a single reportable segment are required to provide all the disclosures required by the amendments in ASU 2023 - 07 and existing segment disclosures in ASC 280. ASU 2023 - 07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted ASU 2023 - 07 as required for the year ended December 31, 2024. The adoption required the Company to provide additional disclosures, but otherwise it does not materially impact the accompanying financial statements.

In December 2023, the FASB issued ASU No. 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” which requires two primary enhancements of 1) disaggregated information on a reporting entity’s effective tax rate reconciliation, and 2) information on cash income taxes paid. Additionally, specific disclosures related to unrecognized tax benefits and indefinite reinvestment assertions were removed. For public business entities, the new requirements will be effective for annual periods beginning after December 15, 2024. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the effect of adopting this ASU.

NOTE 3 - GOING CONCERN CHANGE

With the acquisition of Hangzhou Mai Jin Li Biotechnology Co., Ltd on March 3, 2023, the Company has reported five consecutive quarters of operating profits and positive cash flows from operations as of June 30, 2024. As of June 30, 2024, the Company is no longer considered to have a going concern.

As reflected in the accompanying financial statements, the Company had an accumulated deficit at March 31, 2025 of \$9,090,315 since inception as the Company is assimilating two new businesses into the operations. The Company’s results have improved since the July 13, 2021 acquisition of Panjin Chunqiu Century Industrial Co., Ltd and the acquisition of Hangzhou Mai Jin Li Biotechnology Co., Ltd on March 3, 2023. The Company generated \$860,200 revenues and \$31,335 net income for the three months ended March 31, 2025.

NOTE 4 – PATENT

On July 1, 2022, the Company acquired a Chinese patent for an internet logistics management device. The initial cost of the patent was \$2,607, which will be amortized over the 10-year patent life. The annual patent amortization expense is \$253. The Company reported amortization expenses of \$195 and \$176 for the three months ended March 31, 2025 and 2024, respectively. A Chinese third-party appraisal firm valued the Patent at 10,000,000 CNY (\$1,493,000 USD). The patent balance net of accumulated amortization was \$806 and \$986 at March 31, 2025 and December 31, 2024, respectively, in the accompanying consolidated balance sheet.

NOTE 5 – CONVERTIBLE NOTES PAYABLE

On June 29, 2017, the Company signed a Convertible Promissory Note (the Note) in connection with a long-term loan received from a related party controlled by the Company’s former CEO (Holder) for a total of One Hundred Thousand and 00/100 Dollars (\$100,000.00). The Note is payable together with interest thereon at the rate of five percent (5%) per annum on the unpaid balance.

Maturity Date; Interest Payments.

All outstanding principal together with interest on the Note shall be due June 29, 2022 (“Maturity Date”). The Company shall make quarterly interest payments of Five Hundred Dollars (\$500.00), commencing August 1, 2017, and continuing on the first calendar day of each succeeding three months during the term of the Note or until paid in full, provided, however, that the first interest payment hereunder shall also include any unpaid interest between the date of the Note and June 29, 2022. As of March 31, 2025, no interest has been paid.

Conversion of Principal and Interest Owed.

Optional Conversion into Common Stock. Either of the Holder or the Company, each in its sole discretion and election, may convert any part or all of the outstanding principal and/or interest on this Note into shares of common stock of the Company obtained by dividing (i) any amount of part or all of the outstanding principal and/or interest on the Note, by (ii) the 10-day VWAP of Company common stock prior to the date of conversion; provided, however, that the price of conversion shall not be less than \$0.000001 per share. The Company follows the guidance of ASC Subtopic 470-20 Debt with Conversion and Other Options to evaluate as to whether beneficial conversion feature exists. The Management concluded that the issuance of the convertible notes did not contain a beneficial conversion feature. The Company calculated the fair value of the beneficial conversion feature as the difference between the conversion price and the fair market value of the Company's common stock on the date of issuance. The fair value of the conversion option in connection with the note was \$-0-. The unpaid balance and accrued interest was \$138,795 and \$137,562 at March 31, 2025 and December 31, 2024, respectively. The Company is in default on the repayment terms of the promissory note.

NOTE 6 – EQUITY TRANSACTIONS

Shares Authorized and Activity

The Company was established with two classes of stock, common stock – 100,000,000 shares authorized at a par value of \$0.001 and preferred stock 10,000,000 shares authorized at a par value of \$0.001. At March 31, 2025 and December 31, 2024, the Company has 91,641,747 issued and outstanding shares of common stock and -0- shares of preferred stock issued and outstanding.

On March 3, 2023, the Company acquired all the outstanding shares of Hangzhou Mai Jin Li Biotechnology Co., Ltd (“Mai Jin Li”), for 3,000,000 unregistered shares of the Company's common stock. The Company's common stock was valued at \$9,600 or \$0.0032 per share. As of March 31, 2025 the shares have not been issued.

NOTE 7 – RELATED PARTY TRANSACTIONS

Free Office Space

The Company has been provided with office space by its former majority stockholder and chief executive officer at no cost. The management determined that such a cost is nominal and did not recognize the rent expense in its financial statements.

Stockholder Advances

The Company's stockholders have directly paid to vendors certain expenditures of the Company. The balance due to the stockholders is \$175,329 and \$174,449 at March 31, 2025 and December 31, 2024, respectively, and recorded as stockholder advances in the accompanying consolidated balance sheets. The advances are due on demand and do not provide interest.

NOTE 8 - SEGMENT INFORMATION

The company operates primarily in two distinct business segments being selling goods and services on the internet and the production, processing, distribution and professional technical consulting services of soft capsules for supplements.

The Company's segment profit or loss is measured using gross profit, which is the primary performance metric utilized by management to evaluate the financial results of each reportable segment. For segment reporting purposes, gross profit is calculated as the difference between segment revenue and the direct costs associated with specific projects or contracts. These direct costs include materials, labor, subcontractors, and other project-specific expenses directly attributable to the activities of each segment.

The financial performance of each segment is regularly reviewed by the Chief Executive Officer (CEO). The CODM of the Company is Zhi Cao, CEO. The Company's segment disclosures are presented in accordance with the guidance set forth in ASC 280, *Segment reporting*. Specifically, the disclosures comply with the requirements outlined in ASC 280-10-50-22 through 50-26, which mandate that an entity disclose certain information about its operating segments to enable users of the financial statements to understand the financial performance of different parts of the business.

In accordance with ASC 280-10-50-22, the Company discloses financial information for each reportable segment, including revenue, operating profit or loss, and other significant items that are used by the chief operating decision maker (CODM) in assessing the performance and making decisions about the allocation of resources. The Company identifies its reportable segments based on the internal management structure, and all relevant information is disclosed in the segment footnote as required.

In accordance with ASC 280-10-50-29, the disclosures also adhere to the requirements of which mandate that the financial information provided for each segment should include items such as capital expenditures, depreciation, and amortization, when appropriate. The disclosures reflect the performance and financial position of each segment, and a reconciliation of segment totals to the overall consolidated financial results, including total segment profit or loss and other significant disclosures.

The Company's segment disclosures are presented in accordance with the requirements set forth in ASC 280-10-50-30(b) and (c), which specify the need to disclose the total of reportable segments' profit or loss, as well as the basis of measurement used to determine the segment results.

In accordance with ASC 280-10-50-30(b), the Company provides the total of profit or loss for all reportable segments, which reflects the combined operating results for each reportable segment included in the financial statements. The total segment profit or loss represents the aggregation of segment results before the allocation of corporate expenses and certain other items not attributable to specific segments.

As required by ASC 280-10-50-30(c), the Company has also disclosed the basis of measurement for segment profit or loss. The measure used to assess segment performance and allocate resources is operating income (or loss), which includes revenues, cost of sales, and directly attributable operating expenses for each segment. The operating income (or loss) for each reportable segment is reviewed by the Company's chief operating decision maker (CODM) and serves as the primary performance metric used in resource allocation and operational decision-making.

Segment information is as follows:

Consolidated Statement of Operations:

For the Three Months Ended March 31, 2025:	Internet Goods and Services	Soft Capsules for Supplements	Corporate	Consolidated
Revenue	\$ 27,671	\$ 832,529	\$ -	\$ 860,200
Cost of Revenue	9,763	669,841	-	679,604
Gross margin	17,908	162,688	-	180,596
Operating expenses:				
Salaries	\$ 5,982	\$ 101,015	\$ -	\$ 106,997
Professional fees	-	-	880	880
Amortization and depreciation expense	2,278	35,121	-	37,399
General and administrative expenses	4,769	496	(28)	5,237
Total operating expenses	13,029	136,632	852	150,513
Net operating income (loss)	4,879	26,056	(852)	30,083
Other income (expense):				
Other income (expense)	277	(286)	-	(9)
Gain on acquisition	-	-	-	-
Interest income (expense)	-	5,870	(1,232)	4,638
Total other income (expense)	277	5,584	(1,232)	4,629
Income before provision for taxes	5,156	31,640	(2,084)	34,712
Provision for income taxes	-	3,377	-	3,377
Net income (loss)	\$ 5,156	\$ 28,263	\$ (2,084)	\$ 31,335

<u>For the Three Months Ended March 31, 2024:</u>	Internet Goods and Services	Soft Capsules for Supplements	Corporate	Consolidated
Revenue	\$ 40,179	\$ 1,016,979	\$ -	\$ 1,057,158
Cost of Revenue	12,103	724,715	-	736,818
Gross margin	28,076	292,264	-	320,340
Operating expenses:				
Salaries	\$ 13,726	\$ 113,492	\$ -	\$ 127,218
Professional fees	-	-	2,990	2,990
Amortization and depreciation expense	1,927	47,318	-	49,245
General and administrative expenses	11,266	55,696	(37)	66,925
Total operating expenses	26,919	216,506	2,953	246,378
Net operating income (loss)	1,157	75,758	(2,953)	73,962
Other income (expense):				
Other income (expense)	402	(24)	-	378
Gain on acquisition	-	-	-	-
Interest income (expense)	1	7,411	(1,247)	6,165
Total other income (expense)	403	7,387	(1,247)	6,543
Income before provision for taxes	1,560	83,145	(4,200)	80,505
Provision for income taxes	-	-	-	-
Net income (loss)	<u>\$ 1,560</u>	<u>\$ 83,145</u>	<u>\$ (4,200)</u>	<u>\$ 80,505</u>

Consolidated Assets:

<u>As of March 31, 2025:</u>	Internet Goods and Services	Soft Capsules for Supplements	Corporate	Consolidated
Assets				
Current assets:				
Cash	25,128	1,139,737	-	1,164,865
Accounts receivable	156,187	902,852	-	1,059,039
Inventory	46,024	148,250	-	194,274
Prepaid expenses	3,837	-	2,250	6,087
Related party receivable	-	-	-	-
Other current assets	(17,195)	7,579	19,089	9,473
Total current assets	<u>232,770</u>	<u>2,198,418</u>	<u>21,339</u>	<u>2,452,527</u>
Other assets				
Property and equipment, net of accumulated depreciation	12,144	118,081	-	130,225
Patents, net of accumulative amortization	806	-	-	806
Goodwill	-	-	78,911	78,911
Other assets	-	19,452	-	19,452
Total other assets	<u>12,950</u>	<u>137,533</u>	<u>78,911</u>	<u>229,394</u>
Total Assets	<u>245,720</u>	<u>2,335,951</u>	<u>100,250</u>	<u>2,681,921</u>

<u>As of December 31, 2024:</u>	<u>Internet Goods and Services</u>	<u>Soft Capsules for Supplements</u>	<u>Corporate</u>	<u>Consolidated</u>
Assets				
Current assets:				
Cash	18,862	1,140,853	-	1,159,715
Accounts receivable	144,567	388,744	-	533,311
Inventory	55,066	223,383	1	278,450
Prepaid expenses	61	-	4,500	4,561
Cash advances to suppliers	10,898	310,221	-	321,119
Related party receivable	-	-	-	-
Other current assets	(17,206)	7,535	19,089	9,418
Total current assets	<u>212,248</u>	<u>2,070,736</u>	<u>23,590</u>	<u>2,306,574</u>
Other assets				
Property and equipment, net of accumulated depreciation	14,043	-	151,155	165,198
Patents, net of accumulative amortization	986	-	-	986
Goodwill	-	-	78,911	78,911
Other assets	-	-	33,357	33,357
Total other assets	<u>15,029</u>	<u>-</u>	<u>263,423</u>	<u>278,452</u>
Total Assets	<u><u>227,277</u></u>	<u><u>2,070,736</u></u>	<u><u>287,013</u></u>	<u><u>2,585,026</u></u>

NOTE 9 – SUBSEQUENT EVENTS

The Company has evaluated all other events occurring subsequently to these financial statements through May 9, 2025 and determined there were no other items to disclose.